
|Articles|February 1, 2001
CME: Offering mifepristone as an abortion option
While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug need to familiarize themselves with the research on its advantages and disadvantages.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG's 2026-27 respiratory virus immunization recommendations in pregnancy, postpartum
2
From PCOS to PMOS: A welcome and more inclusive name
3
Managing PMOS and insulin resistance: From primary care to specialist
4
Kevin Ault, MD, on the extended RSV window in ACOG's 2026-27 immunization guidance
5






